Answers are grounded in this paper and cite their sources.
Review analyzes recurrent bleeding risks in atrial fibrillation patients on anticoagulants, highlighting key predictors.
The review discusses the problem of recurrent bleeding in patients with atrial fibrillation receiving anticoagulant therapy. Anticoagulation determines prognosis of life in patients with atrial fibrillation by preventing ischemic stroke and systemic embolisms. However, at least 15-20% of patients suffer recurrent hemorrhagic complications despite correction of all risk factors and anticoagulation changes. Searching for predictors of recurrent bleeding is extremely relevant, as there is currently no system for stratifying the risk of recurrent hemorrhagic complications. The review analyzes clinical data on the incidence of recurrent bleeding and systematizes risk factors. Some clinical risk factors are unmodifiable that leads to searching for laboratory markers. The review also highlights new possible mechanisms that are promising for study. Data of modern methods of fibrin structure visualization are presented. These findings confirm hypothesis of “unstable” clot as the cause of recurrent bleeding. Data on relationship between gene polymorphism and level of factors determining structure and stability of fibrin (factor XIII, alpha, beta, gamma chains of fibrinogen and fibrinolysis system) are presented.
No takes yet. Share an insight, caveat, or question.
Imomkulov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: